Minghui Pharmaceutical has dosed the first patient in a Phase II trial evaluating the combination of MHB039A (PD-1xVEGF bispecific antibody) and MHB036C (TROP-2 ADC) in advanced non-small cell lung cancer patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.